OTCO International provides consultancy and real estate services, primarily focused on the Indian market, and is currently attempting to diversify into technology, pharmaceuticals, and renewable energy.
The company lacks a competitive advantage, evidenced by a significant decline in revenue and a net margin that is deeply negative on average. There is no evidence of pricing power or switching costs, as the business appears to be a small-scale service provider with volatile and shrinking operations.
Capital allocation is poor; the company has seen a steady erosion of its top line and earnings while maintaining high debt-to-equity levels. Management is currently seeking to borrow up to 100 Crores and convert loans to equity, which would be highly dilutive given the current small scale of operations.
The company's pivot into unrelated sectors like defense and pharma proved to be a value-destroying distraction from its already shrinking core services. Management's decision to convert high-interest related-party loans into equity at a massive scale resulted in catastrophic dilution for minority shareholders. As revenue continued its double-digit decline, the lack of internal controls and high debt levels finally led to a liquidity crisis, rendering the business a hollow shell of its former self.
RichFakir rates OTCO International Ltd's business quality as poor — 1/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, OTCO International Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on OTCO International Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of OTCO International Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →